PolyPid (NASDAQ:PYPD) held its first-quarter earnings conference call on Wednesday.
Below is the complete transcript from the call
The full earnings call is available at https://edge. Summary PolyPid reported a net loss of $7.7 million for Q1 2026, an improvement from a loss of $8.3 million in Q1 2025, with operating expenses showing a minor decrease primarily due to the completion of a Phase 3 trial. The company is in the late stages of strategic partnership discussions in the U.S. and is advancing its NDA submission for DPLEx100, which is expected to be completed imminently, aiming for FDA priority review.
PolyPid’s cash resources are expected to fund operations into the second half of 2026, with an additional strengthening of its balance sheet following the full repayment of a loan facility. The company continues to focus on manufacturing readiness for FDA inspection and commercial readiness, including expanding its presence at major medical conferences and engaging in strategic partnerships. Management remains optimistic about 2026 being a transformative year, with significant milestones anticipated, such as a potential FDA approval and European regulatory advancements.